title: Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection.
abstract: It is well accepted that vaccination by oral administration has many advantages over injected parenteral immunization. The present study focuses on whether oral vaccination with a DNA vaccine could induce protective immunity against respiratory challenge infection. The M1 gene of influenza A virus was used to construct DNA vaccine using pcDNA 3.1(+) plasmid, a eukaryotic expression vector. The cationic liposomes were used to deliver the constructed DNA vaccine. In vitro and in vivo expression of M1 gene was observed in the cell line and in the intestine of orally vaccinated C57BL/6 mice, respectively. It became clear that this type of oral DNA vaccination was capable of inducing both humoral and cellular immune responses, together with an augmentation of IFN-γ production. In addition, oral vaccination with liposome-encapsulated DNA vaccine could protect the mice against respiratory challenge infection. These results suggest that gastrointestinal tract, a constituent member of the common mucosal immune system, is a potent candidate applicable as a DNA vaccine route against virus respiratory diseases.
authors.affiliation: Department of Immunology, School of Basic Medical Science, China Medical University, Shenyang, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.forename: Jianqi
authors.initials: J
authors.lastname: Wu
authors.forename: Bing
authors.initials: B
authors.lastname: Wang
authors.forename: Sheng
authors.initials: S
authors.lastname: Zeng
authors.forename: Feifei
authors.initials: F
authors.lastname: Qi
authors.forename: Changlong
authors.initials: C
authors.lastname: Lu
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kimura
authors.forename: Beixing
authors.initials: B
authors.lastname: Liu
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004195:Disease Models, Animal; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*; D007371:Interferon-gamma / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008081:Liposomes / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009976:Orthomyxoviridae Infections / Q000517:prevention & control*; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*; D014763:Viral Matrix Proteins / Q000235:genetics / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D008081:Liposomes; C488936:M1 protein, Influenza A virus; D019444:Vaccines, DNA; D014763:Viral Matrix Proteins; D007371:Interferon-gamma
keywords: constructed DNA vaccine; influenza; liposome; oral vaccination; protective immunity